(Reuters) – Inovio Pharmaceuticals Inc on Tuesday reported positive interim data from an early-stage study assessing its potential COVID-19 vaccine wherein patients showed immune response and was deemed safe. (https://reut.rs/2NFcNqL)
(Reporting by Trisha Roy in Bengaluru; Editing by Arun Koyyur)
